vs
Side-by-side financial comparison of Dynatrace, Inc. (DT) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
Dynatrace, Inc. is the larger business by last-quarter revenue ($515.5M vs $346.4M, roughly 1.5× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 28.1% vs 7.8%, a 20.3% gap on every dollar of revenue. On growth, Dynatrace, Inc. posted the faster year-over-year revenue change (18.2% vs 4.8%). HAEMONETICS CORP produced more free cash flow last quarter ($209.9M vs $27.2M). Over the past eight quarters, Dynatrace, Inc.'s revenue compounded faster (16.3% CAGR vs 1.5%).
Dynatrace, Inc. is an American multinational technology company that provides an AI-powered observability platform. Their software is used to monitor, analyze, and optimize application performance, software development, cyber security practices, IT infrastructure, and user experience.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
DT vs HAE — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $515.5M | $346.4M |
| Net Profit | $40.1M | $97.3M |
| Gross Margin | 81.4% | 57.2% |
| Operating Margin | 14.1% | 36.1% |
| Net Margin | 7.8% | 28.1% |
| Revenue YoY | 18.2% | 4.8% |
| Net Profit YoY | -88.9% | — |
| EPS (diluted) | $0.13 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $346.4M | ||
| Q4 25 | $515.5M | $339.0M | ||
| Q3 25 | $493.8M | $327.3M | ||
| Q2 25 | $477.3M | $321.4M | ||
| Q1 25 | $445.2M | $330.6M | ||
| Q4 24 | $436.2M | $348.5M | ||
| Q3 24 | $418.1M | $345.5M | ||
| Q2 24 | $399.2M | $336.2M |
| Q1 26 | — | $97.3M | ||
| Q4 25 | $40.1M | $44.7M | ||
| Q3 25 | $57.2M | $38.7M | ||
| Q2 25 | $48.0M | $34.0M | ||
| Q1 25 | $39.3M | $58.0M | ||
| Q4 24 | $361.8M | $37.5M | ||
| Q3 24 | $44.0M | $33.8M | ||
| Q2 24 | $38.6M | $38.4M |
| Q1 26 | — | 57.2% | ||
| Q4 25 | 81.4% | 59.7% | ||
| Q3 25 | 81.8% | 59.5% | ||
| Q2 25 | 82.1% | 59.8% | ||
| Q1 25 | 80.9% | 58.4% | ||
| Q4 24 | 81.1% | 55.5% | ||
| Q3 24 | 81.4% | 54.2% | ||
| Q2 24 | 81.3% | 52.0% |
| Q1 26 | — | 36.1% | ||
| Q4 25 | 14.1% | 19.9% | ||
| Q3 25 | 14.8% | 17.9% | ||
| Q2 25 | 13.1% | 16.8% | ||
| Q1 25 | 9.6% | 21.6% | ||
| Q4 24 | 10.9% | 16.9% | ||
| Q3 24 | 11.2% | 15.0% | ||
| Q2 24 | 10.5% | 11.8% |
| Q1 26 | — | 28.1% | ||
| Q4 25 | 7.8% | 13.2% | ||
| Q3 25 | 11.6% | 11.8% | ||
| Q2 25 | 10.0% | 10.6% | ||
| Q1 25 | 8.8% | 17.5% | ||
| Q4 24 | 82.9% | 10.8% | ||
| Q3 24 | 10.5% | 9.8% | ||
| Q2 24 | 9.7% | 11.4% |
| Q1 26 | — | — | ||
| Q4 25 | $0.13 | $0.95 | ||
| Q3 25 | $0.19 | $0.81 | ||
| Q2 25 | $0.16 | $0.70 | ||
| Q1 25 | $0.12 | $1.17 | ||
| Q4 24 | $1.19 | $0.74 | ||
| Q3 24 | $0.15 | $0.66 | ||
| Q2 24 | $0.13 | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.2B | $245.4M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $2.7B | $796.3M |
| Total Assets | $4.1B | $2.4B |
| Debt / EquityLower = less leverage | — | 1.53× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $245.4M | ||
| Q4 25 | $1.2B | $363.4M | ||
| Q3 25 | $1.3B | $296.4M | ||
| Q2 25 | $1.3B | $292.9M | ||
| Q1 25 | $1.1B | $306.8M | ||
| Q4 24 | $1.0B | $320.8M | ||
| Q3 24 | $1.0B | $299.3M | ||
| Q2 24 | $1.0B | $344.4M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $796.3M | ||
| Q4 25 | $2.7B | $911.5M | ||
| Q3 25 | $2.8B | $849.2M | ||
| Q2 25 | $2.7B | $882.3M | ||
| Q1 25 | $2.6B | $820.8M | ||
| Q4 24 | $2.6B | $906.9M | ||
| Q3 24 | $2.1B | $878.9M | ||
| Q2 24 | $2.1B | $905.4M |
| Q1 26 | — | $2.4B | ||
| Q4 25 | $4.1B | $2.5B | ||
| Q3 25 | $4.1B | $2.4B | ||
| Q2 25 | $4.1B | $2.5B | ||
| Q1 25 | $4.1B | $2.5B | ||
| Q4 24 | $3.7B | $2.5B | ||
| Q3 24 | $3.3B | $2.5B | ||
| Q2 24 | $3.3B | $2.5B |
| Q1 26 | — | 1.53× | ||
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $33.8M | $293.2M |
| Free Cash FlowOCF − Capex | $27.2M | $209.9M |
| FCF MarginFCF / Revenue | 5.3% | 60.6% |
| Capex IntensityCapex / Revenue | 1.3% | 9.5% |
| Cash ConversionOCF / Net Profit | 0.84× | 3.01× |
| TTM Free Cash FlowTrailing 4 quarters | $465.5M | $417.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $293.2M | ||
| Q4 25 | $33.8M | $93.6M | ||
| Q3 25 | $32.0M | $111.3M | ||
| Q2 25 | $269.7M | $17.4M | ||
| Q1 25 | $162.8M | $116.6M | ||
| Q4 24 | $42.2M | $43.8M | ||
| Q3 24 | $23.6M | $48.8M | ||
| Q2 24 | $230.7M | $-27.4M |
| Q1 26 | — | $209.9M | ||
| Q4 25 | $27.2M | $87.2M | ||
| Q3 25 | $27.8M | $106.3M | ||
| Q2 25 | $262.2M | $13.6M | ||
| Q1 25 | $148.2M | $100.9M | ||
| Q4 24 | $37.6M | $35.2M | ||
| Q3 24 | $20.1M | $39.4M | ||
| Q2 24 | $227.4M | $-33.1M |
| Q1 26 | — | 60.6% | ||
| Q4 25 | 5.3% | 25.7% | ||
| Q3 25 | 5.6% | 32.5% | ||
| Q2 25 | 54.9% | 4.2% | ||
| Q1 25 | 33.3% | 30.5% | ||
| Q4 24 | 8.6% | 10.1% | ||
| Q3 24 | 4.8% | 11.4% | ||
| Q2 24 | 57.0% | -9.8% |
| Q1 26 | — | 9.5% | ||
| Q4 25 | 1.3% | 1.9% | ||
| Q3 25 | 0.8% | 1.5% | ||
| Q2 25 | 1.6% | 1.2% | ||
| Q1 25 | 3.3% | 4.7% | ||
| Q4 24 | 1.1% | 2.5% | ||
| Q3 24 | 0.8% | 2.7% | ||
| Q2 24 | 0.8% | 1.7% |
| Q1 26 | — | 3.01× | ||
| Q4 25 | 0.84× | 2.09× | ||
| Q3 25 | 0.56× | 2.88× | ||
| Q2 25 | 5.62× | 0.51× | ||
| Q1 25 | 4.14× | 2.01× | ||
| Q4 24 | 0.12× | 1.17× | ||
| Q3 24 | 0.54× | 1.44× | ||
| Q2 24 | 5.97× | -0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DT
| Subscription And Circulation | $493.4M | 96% |
| Services | $22.1M | 4% |
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
